[18F]-Fluorodeoxyglucose PET/CT imaging as a marker of carotid plaque inflammation: Comparison to immunohistology and relationship to acuity of events

BACKGROUND

[18F]-fluorodeoxyglucose (¹⁸FDG) uptake imaged with positron emission tomography (PET) and computed tomography (CT) may serve as a biomarker of plaque inflammation. This study evaluated the relationship between carotid plaque ¹⁸FDG uptake and a) intraplaque expression of macrophage and macrophage-like cellular CD68 immunohistology; b) intraplaque inflammatory burden using leukocyte-sensitive CD45 immunohistology; c) symptomatic patient presentation; d) time from last cerebrovascular event.

METHODS

54 patients scheduled for carotid endarterectomy underwent ¹⁸FDG PET/CT imaging. Maximum 18FDG uptake (SUV_max) and tissue-to-blood ratio (TBR_max) was measured for carotid plaques. Quantitative immunohistological analysis of macrophage-like cell expression (CD68) and leukocyte content (CD45) was performed.

RESULTS

¹⁸FDG uptake was related to CD68 macrophage expression (TBR_max: r = 0.51, p < 0.001), and total-plaque leukocyte CD45 expression (TBR_max: r = 0.632, p = 0.009, p < 0.001). ¹⁸FDG TBR_max uptake in carotid plaque associated with patient symptoms was greater than asymptomatic plaque (3.58 ± 1.01 vs. 3.13 ± 1.10, p = 0.008). ¹⁸FDG uptake differed between an acuity threshold of <90 days and >90 days (SUV_max:3.15 ± 0.87 vs. 2.52 ± 0.45, p = 0.015).

CONCLUSIONS

In this CAIN cohort, ¹⁸FDG uptake imaged with PET/CT serves a surrogate marker of intraplaque inflammatory macrophage, macrophage-like cell and leukocyte burden. 18FDG uptake is greater in plaque associated with patient symptoms and those with recent cerebrovascular events. Future studies are needed to relate ¹⁸FDG uptake and disease progression.

Cardiac PET: metabolic and functional imaging of the myocardium

Cardiac PET has evolved over the past 30 years to gain wider acceptance as a valuable modality for a variety of cardiac conditions. Wider availability of scanners as well as changes in reimbursement policies in more recent years has further increased its use. Moreover, with the emergence of novel radionuclides as well as further advances in scanner technology, the use of cardiac PET can be expected to increase further in both clinical practice and the research arena. PET has demonstrated superior diagnostic accuracy for the diagnosis of coronary artery disease in comparison with single-photon emission tomography while it provides robust prognostic value. The addition of absolute flow quantification increases sensitivity for 3-vessel disease as well as providing incremental functional and prognostic information. Metabolic imaging using (18)F-fluorodeoxyglucose can be used to guide revascularization in the setting of heart failure and also to detect active inflammation in conditions such as cardiac sarcoidosis and within atherosclerotic plaque, improving our understanding of the processes that underlie these conditions. However, although the pace of new developments is rapid, there remains a gap in evidence for many of these advances and further studies are required.

Abstract 311: CRP is Probably Not Causal in Atherosclerosis

Background: C-reactive protein (CRP) is thought to predict increased cardiovascular risk. However, the question of a causal relation to atherosclerosis is in doubt. We studied the relation of CRP to carotid total plaque area (TPA) and stenosis, and to plaque inflammation.

Methods: In 527 patients with measurement of cardiovascular risk factors and CRP, linear regression was used to assess the relation of CRP to total plaque area (TPA) and stenosis. In a subset of patients scheduled for carotid endarterectomy, preoperative PET/CT with 18F- FDG was used to assess plaque inflammation, validated in endarterectomy specimens.

Results: Mean age (SD) was 63.3 (12.27); 44.4% were female, 12.7% diabetic. 4.4% of patients had no plaque; in the rest it ranged from 1 to 788 mm2; median 102 mm2, interquartile range (IQR) 215 mm2. TPA > 361 mm2 was present in 10% of patients. Internal carotid (ICA) stenosis >= 60% was present in 38.3%; 34 had occlusion of one ICA; 1 had bilateral occlusion. Mean (SD) percent carotid stenosis (sum of right + left ICA) was 69.11 (56.0)%. Median hsCRP was 2.7; IQR 3.7. In stepwise linear multiple regression significant predictors of TPA (R2= 0.367, p< 0.00001) were age, smoking pack-years (pk-yrs), systolic blood pressure (SysBP), antihypertensive medication (BPMed), sex, lipid medication (LipMed) (in order of significance); CRP was excluded with p=0.35. Significant predictors of stenosis (R2 =0.226, p< 0.00001) were age, LipMed, pk-yrs, BPMed, SysBP. CRP was excluded with p=0.963. In 20 endarterectomy specimens, the direct burden of inflammation, as quantified by CD68 immunohistology, correlated with maximum 18FDG uptake (r=0.716, p<0.001). There was no evidence of a correlation between CRP and CD68 (r=0.159, p=0.50), nor with maximum 18FDG uptake (r=0.238, p=0.31). Furthermore, FDG was more strongly correlated with CD68 than CRP (p=0.02.CRP was inversely related to the extent of fibrous tissue (r=0.549, p=0.034).

Conclusion: CRP was not associated with plaque inflammation, TPA, or stenosis of the carotid arteries. CRP is probably not a causal factor in atherosclerosis.

CT vs SPECT: CT is the first-line test for the diagnosis and prognosis of stable coronary artery disease

Non-invasive cardiac imaging is pivotal in the diagnosis and prognosis of patients with stable CAD. Nuclear SPECT, PET, stress echocardiography and more recently cardiac magnetic resonance imaging have been utilized with excellent diagnostic accuracy. However, along with their inherent individual limitations, most modalities detect ischemia but lack the ability to define coronary anatomy or evaluate for subclinical atherosclerosis. A modality that not only accurately diagnoses obstructive CAD and also facilitates early identification of non-obstructive CAD may be of interest because it may allow for earlier aggressive risk factor modification and primary prevention. Cardiac computerized tomographic angiography (CCTA) has the potential to accurately detect or exclude luminal stenosis, as well as identify and quantify subclinical atherosclerosis in the absence if luminal narrowing. However CCTA, being a relatively a new modality, has less supporting evidence when compared to more mature modalities such as SPECT. Therefore, the question that begs to be addressed is whether CCTA can be utilized as a first line test in establishing the diagnosis and prognosis of CAD.

The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis

Cardiac sarcoidosis (CS) has gained significant interest in recent years with the emergence of advanced imaging modalities such as MRI and F(18)-fluorodeoxyglucose-positron emission tomography (FDG-PET) as modalities to aid in the diagnosis of this condition. CS remains a difficult condition to diagnose, particularly in cases of isolated cardiac involvement and it can present with a broad spectrum of clinical syndromes. Furthermore, the appropriate management of these patients remains controversial. FDG-PET has a potential role not only in diagnosis of CS but also in directing further therapies, facilitating the decision to start immunosuppression and monitoring the response to it. In this article, we discuss when to consider FDG-PET, outline the current optimal patient preparation and scanning protocols and then, using case examples, discuss the use of FDG-PET in follow-up of patients with known or suspected CS. We also outline how PET can influence management decisions in these patients.

Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see

Prodigious efforts and landmark discoveries have led toward significant advances in our understanding of atherosclerosis. Despite significant efforts, atherosclerosis continues globally to be a leading cause of mortality and reduced quality of life. With surges in the prevalence of obesity and diabetes, atherosclerosis is expected to have an even more pronounced impact upon the global burden of disease. It is imperative to develop strategies for the early detection of disease. Positron emission tomography (PET) imaging utilizing [(18)F]fluorodeoxyglucose (FDG) may provide a non-invasive means of characterizing inflammatory activity within atherosclerotic plaque, thus serving as a surrogate biomarker for detecting vulnerable plaque. The aim of this review is to explore the rationale for performing FDG imaging, provide an overview into the mechanism of action, and summarize findings from the early application of FDG PET imaging in the clinical setting to evaluate vascular disease. Alternative imaging biomarkers and approaches are briefly discussed.

A new approach towards improved visualization of myocardial edema using T2-weighted imaging: a cardiovascular magnetic resonance (CMR) study

PURPOSE

To compare T2-weighted cardiovascular magnetic resonance (CMR) imaging with AASPIR (asymmetric adiabatic spectral inversion recovery) and STIR (short T1 inversion recovery) for myocardial signal intensity, image quality, and fat suppression.

MATERIALS AND METHODS

Forty consecutive patients (47 ± 16 years old) referred by cardiologists for CMR-based myocardial tissue characterization were scanned with both STIR and AASPIR T2-weighted imaging approaches. Signal intensity of left ventricular myocardium was normalized to a region of interest generating a signal-to-noise ratio (SNR). In six patients with regional edema on STIR the contrast-to-noise ratio (CNR) was assessed. Two independent observers used a scoring system to evaluate image quality and artifact suppression. Six healthy volunteers (three males, 32 ± 7 years) were recruited to compare fat suppression between AASPIR and STIR.

RESULTS

SNR of AASPIR was greater than STIR for basal (128 ± 44 vs. 83 ± 40, P < 0.001), mid- (144 ± 65 vs. 96 ± 39, P < 0.01), and apical (145 ± 59 vs. 105 ± 35, P < 0.05) myocardium. Improved image quality and greater suppression of artifacts was demonstrated with AASPIR. In patients with regional edema, CNR increased by 49% with AASPIR, while SNR of pericardial fat did not differ (44 ± 39 vs. 33 ± 30, P > 0.05).

CONCLUSION

Our findings support the implementation of an AASPIR-based approach for T2-weighted imaging due to improved pericardial fat suppression, image quality, and artifact suppression with greater CNR and SNR.